Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jun 07, 2014 11:19am

141 Views

Post# 22639942

RE:Trading Zenith Shares: FYI

Great work GV. Thanks.

So there is a basis for liquidity. That is great.

What really angers me is that a good shareholder like you had to go and pull teeth to get this information. The management of this company is incompetent or mis-guided in regards, at least, to communications with shareholders.

RVX/Zenith management should have pro-actively communicated this to Zenith shareholders along with the processes involved.

So this could establish a trading basis for Zenith. I wonder who they will be publishing bids and asks, etc. I'll have to check the site.

Thanks for your post.
Cheers
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China